Advisory Research Inc Blueprint Medicines Corp Transaction History

Advisory Research Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$43.96 - $92.84 $662,389 - $1.4 Million	15,068 Added 347.83%	19,400 $1.79 Million
Q3 2023 Nov 13, 2023	BUY	$46.9 - $66.0 $203,170 - $285,912	4,332 New	4,332 $217,000
Q2 2018 Aug 14, 2018	SELL	$60.96 - $101.18 $843,320 - $1.4 Million	-13,834 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$73.28 - $102.95 $560,298 - $787,155	-7,646 Reduced 35.6%	13,834 $1.27 Million
Q4 2017 Feb 08, 2018	BUY	$62.91 - $88.32 $277,747 - $389,932	4,415 Added 25.87%	21,480 $1.62 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $723,044 - $1.19 Million	17,065	17,065 $1.19 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.22B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.